CRNX earnings date and last-quarter result: last quarter miss, P/E -16.29. Updated 2026-07-23.
Crinetics Pharmaceuticals (CRNX) Research Hub
Crinetics Pharmaceuticals (CRNX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-01, shares last closed at 84.95 USD (+0.13%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -16.29, market cap 8.88B. This hub links to the full technical, earnings and options research available for CRNX.
Last updated 2026-09-01 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 84.95 USD (+0.13%) |
| 52-week range | 34.38 USD – 84.95 USD |
| Trend regime | Range |
| 14-day RSI | 77.4 (Overbought) |
| Trailing P/E | -16.29 |
| Market cap | 8.88B |
| Dividend yield | 0.00% |
Available research for CRNX
Covered Call on CRNX: how it works, illustrative setup around the real 84.95 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRNX: how it works, illustrative setup around the real 84.95 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRNX: how it works, illustrative setup around the real 84.95 USD price, max profit/loss, breakeven and when to use it. Educational.
CRNX technical analysis: range, last 84.95 USD, RSI 77.4, 52w range 34.38 USD–84.95 USD, real support/resistance. Updated 2026-09-01.
More on SniperIQ
Frequently asked questions
What sector is CRNX in?
Crinetics Pharmaceuticals (CRNX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CRNX in an uptrend or downtrend?
As of 2026-09-01, CRNX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRNX's trailing P/E ratio?
CRNX's trailing P/E is -16.29, with a market cap of 8.88B. See the earnings research page for full valuation detail.